October 15, 2016
Pfizer Inc. announced that three abstracts for XELJANZ® (tofacitinib citrate), being investigated in moderate to severe ulcerative colitis (UC), were presented at the United European Gastroenterology Week (UEG Week 2016), October 15-19 in Vienna, Austria. The tofacitinib presentations highlighted new research results from the Phase 3 Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Induction trials, including one oral presentation looking at the impact of prior treatment with tumor necrosis factor inhibitors (TNFi) on efficacy endpoints. Furthermore, two abstracts were accepted as poster presentations, highlighting results by endoscopic response, and onset of action, respectively.
Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Inc., said: “The new data to be presented at UEG Week deepen our understanding of the efficacy and safety profile of tofacitinib in ulcerative colitis. We know there is a significant unmet need in the UC community for additional treatment options and, if approved, tofacitinib may have the potential to offer patients and their physicians an oral treatment option that could address these unmet needs in the course of the disease.”
Tofacitinib is the first in a new class of medicines called Janus kinase (JAK) inhibitors under investigation for treating moderate to severe UC. Tofacitinib is a small molecule taken as a pill. It works on specific inflammatory responses thought to play a role in the inflammation connected with UC.